Overview

A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease

Status:
Terminated
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular disease events, when compared to atorvastatin alone, in patients with coronary heart disease or risk equivalents
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Treatments:
Atorvastatin
Atorvastatin Calcium
Torcetrapib